Our website uses cookies to improve and personalize your experience and to display ads (if any). Our website may also include third-party cookies from services such as Google AdSense, Google Analytics, and YouTube. By using the website, you consent to the use of cookies. We have updated our Privacy Policy. Please click the button to view our Privacy Policy.

AI-based Deliverome project finds 1,108 candidate drug targets missing from reference databases

AI-based Deliverome project finds 1,108 candidate drug targets missing from reference databases
Contents
  1. Databases that disagree
  2. How the tool works
  3. An example: the KLK2 protein
  4. An open resource
  5. References

Over 65% of approved medicines function by attaching to proteins on the exterior of human cells, although primary biological databases fail to agree on their actual presence. The Deliverome Project, which operates as an open research initiative, applied artificial intelligence to analyze existing literature and construct a comprehensive map of the human surfaceome, representing the complete array of cell surface proteins.

The map pinpoints 1,108 candidate proteins that are absent across all five primary reference databases yet backed by published research. Released in October 2026 as a preprint on bioRxiv, these insights lack formal peer review so far, meaning the proteins remain candidates instead of verified targets.

Databases that disagree

The team compared five databases: UniProt, GO CC, the Human Protein Atlas, the Cell Surface Protein Atlas and SURFY. Together they list 5,546 surface proteins, but all five agree on only 188, according to the Hertz Foundation.

How the tool works

Co-founders Becca Carlson and Bobby Hollingsworth developed an artificial intelligence agent powered by the Claude Sonnet 4.6 model. The system examines scientific literature to ascertain if a given protein resides on the cell surface.

On SurfaceBench, a hand-labeled set of 147 proteins, the agent classified 95.7% correctly. UniProt, the best-performing database, scored about 90%.

An example: the KLK2 protein

All five databases classify the protein KLK2 as absent from the cell surface. However, research has found a membrane-anchored form enriched in prostate cancer, and an experimental therapy targeting it is in Phase 3 trials. Deliverome classifies KLK2 as able to appear on the surface under certain conditions.

An open resource

The map is free to explore in Open View, an interactive tool that shows each protein alongside its supporting research. The project also offers a public API and open-source code.

“My hope is that this will help people develop drugs that are more diverse and serve more patients and more indications,” said Carlson, a 2017 Hertz Fellow and the project’s co-CEO.

Deliverome launched on May 27, 2026, backed by $5 million in seed capital originating from the Astera Institute. Operating as a Focused Research Organization, it utilizes a framework tailored to roll out public research instruments inside roughly half a decade. Investigators affiliated with Coral Biosciences additionally contributed as co-authors on the preprint.

References

By Nuria Calderon